The domestic pharmaceutical industry is changing, and a large number of pharmaceutical executives have changed

【Pharmaceutical Network Industry News】Recently, Xinhua Pharmaceutical announced that Zhang Daiming, the former chairman of the company, resigned as chairman of the board of directors and other positions of the company, and the chairman of the board of directors was taken over by He Tongqing, the former deputy general manager of the company
.

At the same time, Xu Wenhui was appointed as the general manager
of the company.

Zhang Daiming, the former chairman of the company, informed the board that his resignation was due to his plans to retire
.

On the same day, Xinhua Pharmaceutical also announced the departure and appointment
of a number of deputy general managers.

Deputy General Managers He Tongqing, Wang Xiaolong and Du Deqing submitted applications for resignation, and Liu Xuesong and Kou Zuxing were appointed as deputy general managers
.

It is worth noting that this is the second recent major executive change
of Xinhua Pharmaceutical.

On July 1, Du Deping, the former director and general manager of Xinhua Pharmaceutical, resigned from all positions
in Xinhua Pharmaceutical due to job changes.

For the frequent changes in the senior management, Xinhua Pharmaceutical insiders revealed that mainly to achieve a smooth transition, the executives appointed this time have basically worked for many years
.

It is reported that the executives selected this time are selected after the competition for posts and then selected through various prescribed processes, and their abilities in all aspects have also been widely recognized by
the company's employees.

In fact, in recent years, the senior management of domestic pharmaceutical companies has changed frequently, and a large number of senior executives such as general managers of pharmaceutical companies have resigned
due to personal reasons and work adjustments.

For example, on September 14, Jiaying Pharmaceutical issued an announcement that Zhurai resigned as general manager of the company for personal reasons
.

After his resignation, Jurai continued to serve as chairman of the
company.

On September 9, Yuyue Medical announced that Ms.
Zhu Hong resigned as the deputy general manager of the company on September 9, 2022 due to personal reasons
.

Will no longer hold any position in the
company.

On September 7, Rongyu Group issued an announcement that considering the company's business development and work adjustment needs, Mr.
Ding Ning applied to resign as the general manager of the
company.

After his resignation, he will serve as the vice chairman of the company's wholly-owned subsidiary, Zhiyu Medical
.

On September 6, Xiangyu Medical announced that Wei Zuoqin, deputy general manager and secretary of the board of directors of the company, resigned and no longer holds any position in the
company.

During the vacancy period of the secretary of the board of directors, Mr.
He Yongzheng, the chairman of the board of directors (legal representative) of the company, will act as the secretary of the board of directors
.

.
.
.
.
.
.
From the above point of view, since September, a large number of pharmaceutical executives have "left"
.

According to incomplete statistics, in fact, in the past August, a total of 37 pharmaceutical executives announced their departures
.

In July, more than 40 pharmaceutical executives resigned
.

Industry insiders said that the departure of senior executives has the reasons for personal development and corporate strategic adjustment on the one hand; On the other hand, it also reflects the changes in
the environment of the pharmaceutical industry.

It is worth noting that from the perspective of some of the pharmaceutical companies whose general managers have left are innovative drug companies, and some are traditional Chinese medicine companies, which fully shows that in the context of the changeable pharmaceutical environment, both traditional pharmaceutical companies and innovative drug companies are facing severe challenges
.

In general, the frequent changes in senior management in the pharmaceutical industry are closely related to
the development of the industry.

In recent years, under the continuous promotion of medical reform policies, the domestic pharmaceutical industry is undergoing earth-shaking changes, which has also led to the accelerated transformation
of pharmaceutical companies.

In the future, while enterprises continue to adjust their development strategies, active personnel adjustments will continue
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.